Austrian Agency for Health and Food Safety, Vienna, Austria.
WHO Collaborating Centre for Gonorrhoea and Other STIs, National Reference Laboratory for STIs, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Euro Surveill. 2022 Jun;27(24). doi: 10.2807/1560-7917.ES.2022.27.24.2200455.
We describe a gonorrhoea case with ceftriaxone plus high-level azithromycin resistance. In April 2022, an Austrian heterosexual male was diagnosed with gonorrhoea after sexual intercourse with a female sex worker in Cambodia. Recommended treatment with ceftriaxone (1 g) plus azithromycin (1.5 g) possibly failed. Worryingly, this is the second strain in an Asian genomic sublineage including high-level azithromycin-resistant strains that developed ceftriaxone resistance by acquisition of mosaic -60.001. Enhanced resistance surveillance and actions are imperative to prevent spread.
我们描述了一例对头孢曲松加高水平阿奇霉素耐药的淋病病例。2022 年 4 月，一名奥地利异性恋男性与柬埔寨一名性工作者发生性行为后被诊断患有淋病。推荐使用头孢曲松（1 g）加阿奇霉素（1.5 g）治疗，但可能无效。令人担忧的是，这是第二个在亚洲基因组亚谱系中出现的菌株，该亚谱系包括高水平阿奇霉素耐药菌株，这些菌株通过获得马赛克 -60.001 而对头孢曲松产生耐药性。加强耐药性监测和采取行动是防止传播的必要措施。
